The week in billion-dollar deals began with a pair of billion-dollar hostile bids that failed to win over their targets. Endo International lost out to Valeant Pharmaceuticals International’s new deal for Salix Pharmaceuticals, while Simon Property Group’s $22.4 billion offer for retail real estate investment trust Macerich Co. was simply too low.
The Am Law Daily noted a week ago Skadden, Arps, Slate, Meagher & Flom’s roles representing Endo and Valeant on their competing bids for Salix, a dual representation that The Wall Street Journal and Reuters subsequently took note of, which now concludes with Valeant the victor after upping its purchase price for Salix. The amended deal is expected to close April 1.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
